Ann: Appendix 4C - quarterly, page-45

The SP is primarily because of unexplained delays with the clinical trial (trial 7) and a lack of communication. A CR is a risk, but if they wrap up the trial with good results prior to the end of Q2, as anticipated, then I reckon there’ll be money thrown at them. The lack of transparency is my biggest gripe. We never knew about the biomarker issue until after it was solved, there’s an internal review going on we’re not privy to, a new CEO out of the blue and unexplained delays. As you said tho, the potential is massive and the MC is very low.